pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

25,011 catalysts · 5,303 approval · 5,000 device 510k · 4,728 grant · 3,189 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 0 catalysts2026-08-12: 82 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 3 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
from 2023-04-18×clear all
type
  • approval5,303
  • device 510k5,000
  • grant4,728
  • 8k filing3,189
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings584
  • phase 2 completion172
  • therapy area
    • Oncology148
    • Infectious Disease46
    • Cardiology37
    • Immunology35
    • Dermatology31
    • Pulmonology22
    • Women's Health19
    • Ophthalmology16
    • Pain15

    Week of Aug 14, 2023

    13
    ›Aug 14, 2023approval1095d agoELREXFIO (ELRANATAMAB) — FDA approvalelranatamab

    Sponsor: PFIZER INC. Form: SOLUTION. Route: INJECTION

    full page →elranatamab →fda approvals ↗
    ›Aug 14, 2023approval1095d agoAMJEVITA (ADALIMUMAB-ATTO) — FDA approvalAMJEVITA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INJECTION

    full page →AMJEVITA →fda approvals ↗
    ›Aug 15, 2023approval1094d agoVONJO (PACRITINIB CITRATE) — FDA approvalpacritinib

    Sponsor: SOBI. Form: CAPSULE. Route: ORAL

    full page →pacritinib →fda approvals ↗
    ›Aug 16, 2023approval1093d agoABRILADA (ADALIMUMAB-AFZB) — FDA approvalABRILADA

    Sponsor: PFIZER INC. Form: INJECTABLE. Route: INJECTION

    full page →ABRILADA →fda approvals ↗
    ›Aug 16, 2023approval1093d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: INJECTABLE. Route: INJECTION

    full page →RIFADIN →fda approvals ↗
    ›Aug 16, 2023approval1093d agoRIFATER (ISONIAZID) — FDA approvalRIFATER

    Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL

    full page →RIFATER →fda approvals ↗
    ›Aug 16, 2023approval1093d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: CAPSULE. Route: ORAL

    full page →RIFADIN →fda approvals ↗
    ›Aug 16, 2023approval1093d agoACETAZOLAMIDE — FDA approvalAccord Healthcare Inc

    Sponsor: HIBROW HLTHCARE. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Aug 16, 2023approval1093d agoVOQUEZNA TRIPLE PAK (AMOXICILLIN) — FDA approvalamoxicillin + clarithromycin + vonoprazan

    Sponsor: PHATHOM. Form: CAPSULE, TABLET, TABLET. Route: ORAL

    full page →amoxicillin + clarithromycin + vonoprazan →fda approvals ↗
    ›Aug 16, 2023approval1093d agoVOQUEZNA DUAL PAK (AMOXICILLIN) — FDA approvalamoxicillin + vonoprazan fumarate

    Sponsor: PHATHOM. Form: CAPSULE, TABLET. Route: ORAL

    full page →amoxicillin + vonoprazan fumarate →fda approvals ↗
    ›Aug 17, 2023approval1092d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →remdesivir →fda approvals ↗
    ›Aug 18, 2023approval1091d agoEYLEA HD (AFLIBERCEPT) — FDA approvalEYLEA HD

    Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

    full page →EYLEA HD →fda approvals ↗
    ›Aug 18, 2023approval1091d agoFLUOXETINE HYDROCHLORIDE — FDA approvalFLUOXETINE HYDROCHLORIDE

    Sponsor: AUROBINDO PHARMA LTD. Form: TABLET. Route: ORAL

    full page →FLUOXETINE HYDROCHLORIDE →fda approvals ↗

    Week of Aug 21, 2023

    8
    ›Aug 22, 2023approval1087d agoFOCINVEZ (FOSAPREPITANT DIMEGLUMINE) — FDA approvalAthenex Inc (Inactive)

    Sponsor: STERISCIENCE. Form: SOLUTION. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Aug 23, 2023approval

    Week of Aug 28, 2023

    6
    ›Aug 28, 2023approval1081d agoREBLOZYL (LUSPATERCEPT-AAMT) — FDA approvalluspatercept

    Sponsor: CELGENE CORP. Form: POWDER. Route: SUBCUTANEOUS

    full page →luspatercept →fda approvals ↗
    ›Aug 29, 2023approval

    Week of Sep 4, 2023

    10
    ›Sep 5, 2023approval1073d agoDOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

    Sponsor: MYLAN. Form: TABLET. Route: ORAL

    full page →DOXYCYCLINE HYCLATE →fda approvals ↗
    ›Sep 5, 2023approval

    Week of Sep 11, 2023

    13
    ›Sep 11, 2023approval1067d agoACETAZOLAMIDE — FDA approvalACETAZOLAMIDE

    Sponsor: AJANTA PHARMA LTD. Form: TABLET. Route: ORAL

    full page →ACETAZOLAMIDE →fda approvals ↗
    ›Sep 11, 2023approval
    ← prev
    page 6 of 501
    next →
    1086d ago
    LOSARTAN POTASSIUM — FDA approvalLOSARTAN POTASSIUM

    Sponsor: MICRO LABS. Form: TABLET. Route: ORAL

    full page →LOSARTAN POTASSIUM →fda approvals ↗
    ›Aug 23, 2023approval1086d agoCOMETRIQ (CABOZANTINIB S-MALATE) — FDA approvalcabozantinib s-malate

    Sponsor: EXELIXIS. Form: CAPSULE. Route: ORAL

    full page →cabozantinib s-malate →fda approvals ↗
    ›Aug 23, 2023approval1086d agoVEKLURY (REMDESIVIR) — FDA approvalremdesivir

    Sponsor: GILEAD SCIENCES INC. Form: SOLUTION. Route: INTRAVENOUS

    full page →remdesivir →fda approvals ↗
    ›Aug 24, 2023approval1085d agoTYRUKO (NATALIZUMAB-SZTN) — FDA approvalnatalizumab biosimilar

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →natalizumab biosimilar →fda approvals ↗
    ›Aug 25, 2023approval1084d agoLISDEXAMFETAMINE DIMESYLATE — FDA approvalLISDEXAMFETAMINE DIMESYLATE

    Sponsor: ASCENT PHARMS INC. Form: CAPSULE. Route: ORAL

    full page →LISDEXAMFETAMINE DIMESYLATE →fda approvals ↗
    ›Aug 25, 2023approval1084d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Aug 25, 2023approval1084d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    1080d ago
    MYCOPHENOLATE MOFETIL — FDA approvalMYCOPHENOLATE MOFETIL

    Sponsor: STRIDES PHARMA INTL. Form: FOR SUSPENSION. Route: ORAL

    full page →MYCOPHENOLATE MOFETIL →fda approvals ↗
    ›Aug 29, 2023approval1080d agoISOTRETINOIN — FDA approvalZydus Therapeutics Inc

    Sponsor: ZYDUS PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Aug 31, 2023approval1078d agoMEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalSpexotras

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →Spexotras →fda approvals ↗
    ›Aug 31, 2023approval1078d agoTAFINLAR (DABRAFENIB MESYLATE) — FDA approvaldabrafenib mesylate ODT

    Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL

    full page →dabrafenib mesylate ODT →fda approvals ↗
    ›Aug 31, 2023approval1078d agoALVIMOPAN — FDA approvalALVIMOPAN

    Sponsor: HIKMA. Form: CAPSULE. Route: ORAL

    full page →ALVIMOPAN →fda approvals ↗
    1073d ago
    DOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

    Sponsor: MYLAN. Form: TABLET. Route: ORAL

    full page →DOXYCYCLINE HYCLATE →fda approvals ↗
    ›Sep 5, 2023approval1073d agoDOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

    Sponsor: MYLAN. Form: TABLET. Route: ORAL

    full page →DOXYCYCLINE HYCLATE →fda approvals ↗
    ›Sep 5, 2023approval1073d agoDOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

    Sponsor: MYLAN. Form: TABLET. Route: ORAL

    full page →DOXYCYCLINE HYCLATE →fda approvals ↗
    ›Sep 5, 2023approval1073d agoDOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

    Sponsor: MYLAN. Form: TABLET. Route: ORAL

    full page →DOXYCYCLINE HYCLATE →fda approvals ↗
    ›Sep 5, 2023approval1073d agoDOXYCYCLINE HYCLATE — FDA approvalDOXYCYCLINE HYCLATE

    Sponsor: MYLAN. Form: TABLET. Route: ORAL

    full page →DOXYCYCLINE HYCLATE →fda approvals ↗
    ›Sep 6, 2023approval1072d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

    Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

    full page →YUFLYMA →fda approvals ↗
    ›Sep 8, 2023approval1070d agoXeomin (incobotulinumtoxinA) — FDA approvalMerz Pharmaceuticals LLC

    Sponsor: MERZ PHARMS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Sep 8, 2023approval1070d agoAPHEXDA (MOTIXAFORTIDE ACETATE) — FDA approvalBioLineRx Ltd.

    Sponsor: AYRMID PHARMA. Form: POWDER. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Sep 8, 2023approval1070d agoHYRIMOZ (ADALIMUMAB-ADAZ) — FDA approvalHYRIMOZ

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →HYRIMOZ →fda approvals ↗
    1067d ago
    VORICONAZOLE — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 11, 2023approval1067d agoVORICONAZOLE — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 11, 2023approval1067d agoVORICONAZOLE — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 11, 2023approval1067d agoVORICONAZOLE — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 11, 2023approval1067d agoVORICONAZOLE — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 11, 2023approval1067d agoVORICONAZOLE — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 11, 2023approval1067d agoVORICONAZOLE — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 11, 2023approval1067d agoVORICONAZOLE — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 11, 2023approval1067d agoVORICONAZOLE — FDA approvalMylan Pharmaceuticals Inc

    Sponsor: MYLAN PHARMS INC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 11, 2023approval1067d agoLOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: AUROBINDO PHARMA. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Sep 12, 2023approval1066d agoTRAMADOL HYDROCHLORIDE — FDA approvalTrigen Laboratories Inc

    Sponsor: IPCA LABS LTD. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Sep 12, 2023approval1066d agoSUBLOCADE (BUPRENORPHINE) — FDA approvalbuprenorphine LA

    Sponsor: INDIVIOR. Form: SOLUTION, EXTENDED RELEASE. Route: SUBCUTANEOUS

    full page →buprenorphine LA →fda approvals ↗
    $PFE26.26-1.36%
    $GILD135.56-0.15%
    $PHAT9.1700+7.76%
    $PHAT9.1700+7.76%
    $PFE26.26-1.36%
    $AMGN416.31+0.48%
    $REGN799.43+0.30%
    $EXEL50.53-1.56%
    $GILD135.56-0.15%
    $INDV38.73+0.78%
    $NVS152.51-1.35%
    $BLRX2.8051+1.08%
    $NVS152.51-1.35%